Analysts expect Biomarin Pharmaceutical to report an earnings per share (EPS) of $0.52.
The announcement from Biomarin Pharmaceutical is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Earnings History Snapshot
During the last quarter, the company reported an EPS beat by $0.61, leading to a 7.95% increase in the share price on the subsequent day.
Here's a look at Biomarin Pharmaceutical's past performance and the resulting price change:
Quarter
Q2 2024
Q1 2024
Q4 2023
Q3 2023
EPS Estimate
0.35
0.34
0.23
0.22
EPS Actual
0.96
0.71
0.49
0.46
Price Change %
8.0%
-10.0%
1.0%
-5.0%
Market Performance of Biomarin Pharmaceutical's Stock
Shares of Biomarin Pharmaceutical were trading at $69.73 as of October 25. Over the last 52-week period, shares are down 14.11%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
Insights Shared by Analysts on Biomarin Pharmaceutical
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Biomarin Pharmaceutical.
A total of 27 analyst ratings have been received for Biomarin Pharmaceutical, with the consensus rating being Outperform. ...